The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Predictors for Long-Term Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2024
   Pooled it
2. Evaluating the benefits of adjuvant chemotherapy in patients with pancreatic cancer undergoing radical pancreatectomy after neoadjuvant therapy-a systematic review and meta-analysis.Frontiers in oncology · 2024
   Pooled it
3. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials.ESMO open · 2023
   Pooled it
4. The preoperative HELPP score can be used as a prognostic assessment tool for resectable pancreatic cancer patients, and may be applicable to patients in China as well.Gland surgery · 2025
   Article
5. Therapeutic developments in pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2024
   Review
6. Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma.Cancers · 2023
   Review
7. Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives.World journal of gastrointestinal oncology · 2023
   Review
8. Neoadjuvant therapy for pancreatic cancer.Nature reviews. Clinical oncology · 2023
   Review
9. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study.MedComm · 2023
   Review
10. Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival.Function (Oxford, England) · 2023
    Review
11. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases.Cancer control : journal of the Moffitt Cancer Center
    Article

Corrections and comments

• Comment on
  Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.2022

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as